Customers Worldwide Use Partek Software in their Research

Partek software is used by thousands of customers worldwide to make drug discoveries, study human genetics and disease causes, diagnosis, and treatments. We are proud of the contribution our products continue to make toward their success. The map below shows a small representation of the pharmaceutical, medical, academic, and government facilities currently using Partek products in their research.


What Customers are Saying About Partek


"We have been using Partek software for analysis of microarray data for seven years now and have had microRNA Expression in Ethnic Specific Early Stage Breast Cancer: an Integration and Comparative Analysisnumerous publications from our own laboratory that would not have come about without this software."

Rose-Mary Boustany, MD 
Professor of Pediatrics and Adolescent Medicine, Professor of Biochemistry and Molecular Genetics, Duke Adjunct Professor of Pediatrics, Director, AUBMC Special Kids Clinic and Neurogenetics Program, Division Chief, Pediatric Neurology 
American University of Beirut Medical Center 

Thumbnail of Long Paper

“I use Partek Software because it’s so reactive and easy to use and it enables me to perform analysis sessions ‘live’ with researchers.”

Florent Dumont, PhD
Institut Cochin in Paris






“The ease of use and flexibility of Partek Flow software allows our group to support many different users with computationally-demanding next generation sequencing tasks." 

Meng Li, M.S.
Bioinformatics Specialist
Bioinformatics Services
University of Southern California
Norris Medical Library


Lawrenson Paper Thumbnail
Xian Paper Thumbnail

“Partek has been a remarkably user-friendly and powerful tool for distilling key regulatory pathways governing stem cells from complex arrays of gene expression and genomics data.”

Wa Xian, PhD
McGovern School of Medicine
University of Texas Health Sciences Center



“Partek Genomics Suite is possibly the most user friendly and powerful microarray analysis software on the market right now. It helped us enormously to analyze our data quickly and efficiently.”

Efstathios Giotis, PhD
Imperial College London

Giotis Paper Thumbnail